A detailed history of Bank Of America Corp transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 17,187 shares of IGMS stock, worth $152,792. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,187
Previous 24,319 29.33%
Holding current value
$152,792
Previous $167,000 70.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.28 - $17.68 $44,788 - $126,093
-7,132 Reduced 29.33%
17,187 $284,000
Q2 2024

Aug 14, 2024

BUY
$6.51 - $11.47 $13,325 - $23,479
2,047 Added 9.19%
24,319 $167,000
Q1 2024

May 15, 2024

SELL
$8.68 - $17.36 $21,352 - $42,705
-2,460 Reduced 9.95%
22,272 $214,000
Q4 2023

Feb 14, 2024

BUY
$3.94 - $8.79 $32,012 - $71,418
8,125 Added 48.93%
24,732 $205,000
Q2 2023

Aug 14, 2023

BUY
$8.86 - $14.0 $9,559 - $15,106
1,079 Added 6.95%
16,607 $153,000
Q1 2023

May 12, 2023

SELL
$13.74 - $25.76 $33,608 - $63,008
-2,446 Reduced 13.61%
15,528 $213,000
Q4 2022

Feb 10, 2023

BUY
$15.45 - $26.02 $156,060 - $262,828
10,101 Added 128.3%
17,974 $305,000
Q3 2022

Nov 14, 2022

BUY
$15.42 - $27.01 $14,232 - $24,930
923 Added 13.28%
7,873 $179,000
Q2 2022

Aug 12, 2022

BUY
$13.27 - $25.5 $37,646 - $72,343
2,837 Added 68.98%
6,950 $125,000
Q1 2022

May 16, 2022

SELL
$13.42 - $29.73 $159,993 - $354,441
-11,922 Reduced 74.35%
4,113 $110,000
Q4 2021

Feb 08, 2022

BUY
$27.59 - $66.39 $341,784 - $822,439
12,388 Added 339.68%
16,035 $470,000
Q3 2021

Nov 15, 2021

BUY
$65.76 - $90.65 $41,165 - $56,746
626 Added 20.72%
3,647 $240,000
Q2 2021

Sep 13, 2021

BUY
$57.98 - $96.6 $175,157 - $291,828
3,021 New
3,021 $251,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $258M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.